The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

Study of 39,141 patients with lung cancer or melanoma, including 1,100 patients treated with CTLA-4 inhibitors or programmed cell death-1 inhibitors, found increased risks of cardiac events with these. Absolute risks were higher vs previous pharmacovigilance studies.

European Heart Journal